文献速递妇科生殖医学

大麻二酚用于子宫内膜异位症和慢性盆腔痛的管理

Cannabidiol for the Management of Endometriosis and Chronic Pelvic Pain.
PubMed 文献 · J Minim Invasive Gynecol · 2021-11-25

本综述检索了PubMed、Embase和Cochrane数据库,纳入41篇文献及12篇灰色文献,评估大麻素类产品对子宫内膜异位症和慢性盆腔痛的作用。现有证据多来自实验室研究,结果相互矛盾,人体研究多为易受偏倚影响的调查。英国国家指南因缺乏明确获益证据,不能推荐大麻素类产品用于这些患者。

要点

  • 现有证据多来自模拟大麻素类产品对临床前子宫内膜异位症模型作用的实验室研究,部分显示获益但结果矛盾。
  • 关于女性子宫内膜异位症患者使用大麻或衍生产品的研究很少,多为调查形式且受偏倚影响。
  • 英国国家指南规定大麻素类产品仅可用于有明确发表获益证据且所有其他治疗选择已用尽的病症。

核心结论

  • 现有证据不足以推荐大麻素类产品用于子宫内膜异位症和慢性盆腔痛,需更全面的研究评估内源性大麻素在子宫内膜异位症中的作用后方可推荐或处方。

研究设计与样本

  • 电子检索PubMed、Embase和Cochrane数据库,并检索灰色文献及参考文献列表,初检获264篇文章,最终纳入41篇,另从灰色文献检索和参考文献综述中纳入12篇。

主要发现

  • 多数可用证据来自模拟大麻素类产品对临床前子宫内膜异位症模型作用的实验室研究,部分显示获益但结果相互矛盾。
  • 关于大麻或其衍生产品对子宫内膜异位症女性影响的研究很少,多数为调查形式且受偏倚影响。
  • 长期使用大麻可能造成伤害,可能与「大麻使用障碍」、精神病和情绪障碍相关。

关键数值与推荐

  • 英国国家指南规定大麻素类产品仅可用于有明确发表获益证据的病症,且仅在所有其他治疗选择已用尽时。

临床怎么用

  • 目前英国国家指南因缺乏明确获益证据不能向患者推荐大麻素类产品。
  • 现有子宫内膜异位症治疗方案常影响生育力和/或具有妨碍长期管理的不良反应,大麻素类产品曾被建议为可能规避这些问题的新型治疗选择。
  • 在能够推荐或处方大麻素类产品之前,需对內源性大麻素在子宫内膜异位症背景下的影响进行更全面的研究。

局限性

  • 现有证据多来自实验室研究,结果相互矛盾,人体影响不能必然从这些数据外推。
  • 关于女性子宫内膜异位症患者使用大麻或衍生产品的研究很少,多数为调查形式且受偏倚影响。
  • 缺乏设计良好的稳健研究和随机对照试验评估大麻素类产品治疗子宫内膜异位症的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To review the available literature on the effect of cannabis-based products on the female reproductive system and establish whether there is any evidence that they benefit or harm patients with endometriosis and, therefore, whether there is sufficient evidence to recommend them. DATA SOURCES: An electronic-based search was performed in PubMed, Embase, and the Cochrane Database. Reference lists of articles retrieved were reviewed, and a gray literature search was also performed. METHODS OF STUDY SELECTION: The original database search yielded 264 articles from PubMed, Embase, and the Cochrane Database, of which 41 were included. One hundred sixty-one studies relating to gynecologic malignancy, conditions unrelated to endometriosis, or therapies unrelated to cannabis-based products were excluded. Twelve articles were included from a gray literature search and review of references. TABULATION, INTEGRATION, AND RESULTS: Most available evidence is from laboratory studies aiming to simulate the effects of cannabis-based products on preclinical endometriosis models. Some show evidence of benefit with cannabis-based products. However, results are conflicting, and the impact in humans cannot necessarily be extrapolated from these data. Few studies exist looking at the effect of cannabis or its derived products in women with endometriosis; the majority are in the form of surveys and are affected by bias. National guidance was also reviewed: at present, this dictates that cannabis-based products can only be prescribed for conditions in which there is clear published evidence of benefit and only when all other treatment options have been exhausted. CONCLUSION: Current treatment options for endometriosis often affect fertility and/or have undesirable side effects that impede long-term management. Cannabis-based products have been suggested as a novel therapeutic option that may circumvent these issues. However, there is a paucity of well-designed, robust studies and randomized controlled trials looking at their use in the treatment of endometriosis. In addition, cannabis use has a potential for harm in the long term, with a possible association with "cannabis use disorder," psychosis, and mood disturbances. At present, national guidance cannot recommend cannabis-based products to patients in the UK owing to lack of clear evidence of benefit. More comprehensive research into the impact of endocannabinoids in the context of endometriosis is required before their use can be recommended or prescribed.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Mistry M, Simpson P, Morris E, et al. Cannabidiol for the Management of Endometriosis and Chronic Pelvic Pain. J Minim Invasive Gynecol. 2021. PMID: 34839061. doi:10.1016/j.jmig.2021.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。